Business
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association’s Scientific Sessions
GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral
About this update from Altimmune, Inc.
[{"type":"text","content":"GAITHERSBURG, Md., June 18, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024. Details for the oral presentations are as follows: Session Title:Leveling Up Incretin-Based Therapy in Type 2 DiabetesSession Date/Time:Saturday, June 22, 2024, 4:30 PM - 6:00 PMPresentation Title:Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory LipidsPresenter:John J. Suschak, Ph.D., Senior Director, Translational Science, AltimmunePresentation Date/Time:Saturday, June 22, 2024 at 4:45 pm EDT Session Title:Weighing Opportunities of Incretin-Based Therapy in ObesitySession Date/Time:Sunday, June 23, 2024, 1:30pm - 3:00pmPresentation Title:Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity –A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) TrialPresenter:Louis Aronne, M.D., Professor of Metabolic Research and Professor of Clinical Medicine, Weil Cornell Medical SchoolPresentation Date/Time:Sunday, June 23, 2024 at 1:45 pm EDT The presentation by Dr. Aronne will also be featured in the official Press Program for the American Diabetes Association’s 84th Scientific Sessions. These presentations will be accessible on the Events section of the Altimmune website. About PemvidutidePemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track des...